Salarius Pharmaceuticals, Inc.
SLRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | -$1 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $62 | $116 | $76 | $175 |
| G&A Expenses | $0 | $849 | $1,643 | $1,313 |
| SG&A Expenses | $832 | $849 | $1,643 | $1,313 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $894 | $966 | $1,719 | $1,489 |
| Operating Income | -$895 | -$966 | -$1,719 | -$1,489 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $22 | $8 | $9 | $25 |
| Pre-Tax Income | -$873 | -$958 | -$1,710 | -$1,464 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$873 | -$958 | -$1,710 | -$1,464 |
| % Margin | – | – | – | – |
| EPS | -1.81 | -6.75 | -15.45 | -22.8 |
| % Growth | 73.2% | 56.3% | 32.2% | – |
| EPS Diluted | -1.81 | -6.75 | -15.45 | -22.8 |
| Weighted Avg Shares Out | 482 | 142 | 111 | 64 |
| Weighted Avg Shares Out Dil | 482 | 142 | 111 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $22 | $8 | $9 | $25 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$872 | -$964 | -$1,718 | -$1,488 |
| % Margin | – | – | – | – |